| 12.05. | TRANSCRIPT : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C.. |  |
| 12.05. | NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3- | |
| 11.05. | INFLATION : Have we passed the peak yet? | |
| 11.05. | ANALYST RECOMMENDATIONS : Electronic Arts, Corning, Arrowhead Pharma, Tesla, Wynn Resorts... | |
| 10.05. | TRANSCRIPT : Arrowhead Pharmaceuticals, Inc., Q2 2022 Earnings Call, May 10, 2022 | |
| 10.05. | ARROWHEAD PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND.. | |
| 10.05. | Arrowhead Pharmaceuticals Swings to Profit in Fiscal Q2 as Revenue Rises | |
| 10.05. | Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results | |
| 10.05. | Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six.. | |
| 10.05. | EARNINGS REACTION HISTORY : Arrowhead Pharma Inc, 40.0% Follow-Through Indicator, 6.5% Sen.. | |
| 09.05. | Arrowhead Pharmaceuticals Starts Construction of Manufacturing Facility in Wisconsin | |
| 09.05. | Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Ever.. | |
| 09.05. | Arrowhead Pharmaceuticals, Inc. Breaks Ground on New Manufacturing Facility | |
| 05.05. | ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K) | |
| 02.05. | Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors | |
| 02.05. | Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences | |
| 02.05. | Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors | |
| 27.04. | Arrowhead Pharmaceuticals to Host Pulmonary R&D Day | |
| 26.04. | Arrowhead Pharmaceuticals Launches Phase 2 Study of ARO-ANG3 to Treat Homozygous Famili.. | |
| 26.04. | Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 f.. | |
| 26.04. | Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical.. | |
| 25.04. | ARROWHEAD PHARMACEUTICALS : Dia fda 2022 aro-hif2 | |
| 25.04. | Arrowhead Pharmaceuticals, Vivo Capital Form Joint Venture to Expand Reach of Innovativ.. | |
| 25.04. | ARROWHEAD PHARMACEUTICALS : and Vivo Capital Launch Joint Venture Aimed at Greater China M.. | |
| 25.04. | ARROWHEAD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhib.. | |
| 25.04. | Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China .. | |
| 25.04. | Arrowhead Pharmaceuticals and Vivo Capital Form Joint Venture, Visirna Therapeutics to .. | |
| 20.04. | Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results | |
| 14.04. | ARROWHEAD PHARMACEUTICALS : AACR 2022 ARO-HIF2 Poster | |
| 13.04. | ARROWHEAD PHARMACEUTICALS : APASL 2022 JNJ-3989 in Healthy Chinese | |
| 13.04. | ARROWHEAD PHARMACEUTICALS : APASL 2022 JNJ-3989 in Hepatic Impaired | |
| 13.04. | ARROWHEAD PHARMACEUTICALS : Apasl 2022 jnj-3989 | |
| 07.04. | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4) | |
| 06.04. | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4.. | |
| 04.04. | Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences | |
| 01.04. | Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences | |
| 24.03. | SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Thursday | |
| 24.03. | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Study Potential Treatment f.. | |
| 24.03. | Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for.. | |
| 24.03. | Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a S.. | |
| 18.03. | ARROWHEAD PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for.. | |
| 15.03. | Arrowhead Pharmaceuticals Seeks Regulatory Approval for Trial of Investigational Asthma.. | |
| 15.03. | Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for T.. | |
| 15.03. | Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a S.. | |
| 07.03. | GLASS LEWIS ESG CONTROVERSY ALERT : Arrowhead Pharmaceuticals | |
| 01.03. | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrow.. | |
| 24.02. | Arrowhead Pharmaceuticals Says Patient Enrollment is Complete in Study of Mixed Dyslipi.. | |
| 24.02. | Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 f.. | |
| 24.02. | Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Inves.. | |
| 21.02. | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrow.. | |
| 18.02. | Arrowhead Pharmaceuticals Begins 1/2 Study of Drug to Treat Complement Mediated Disease.. | |
| 18.02. | Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Compleme.. | |
| 18.02. | Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Co.. | |
| 17.02. | ARROWHEAD PHARMACEUTICALS : Initial results from the phase 1 study of ARO-HIF2 to silence .. | |
| 17.02. | Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 | |
| 17.02. | Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 | |
| 14.02. | INSIDER SELL : Arrowhead Pharmaceuticals | |
| 02.02. | TRANSCRIPT : Arrowhead Pharmaceuticals, Inc., Q1 2022 Earnings Call, Feb 02, 2022 | |
| 02.02. | ARROWHEAD PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND.. | |
| 02.02. | Arrowhead Pharmaceuticals Fiscal Q1 Net Loss Widens, Revenue Rises | |
| 02.02. | Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended De.. | |
| 02.02. | ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2022 First Quarter Results - Form 8-K | |
| 02.02. | Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results | |
| 02.02. | Earnings Flash (ARWR) ARROWHEAD PHARMACEUTICALS Reports Q1 Loss $-0.60 | |
| 02.02. | Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Fe.. | |
| 02.02. | EARNINGS REACTION HISTORY : Arrowhead Pharma Inc, 57.1% Follow-Through Indicator, 7.4% Sen.. | |
| 24.01. | Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results | |
| 24.01. | Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline | |
| 24.01. | Arrowhead Pharmaceuticals Announces Closing of Agreement with Glaxosmithkline | |
| 21.01. | Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results | |
| 12.01. | Arrowhead Pharmaceuticals Commences Dosing in Phase 3 Trial of Treatment for Familial C.. | |
| 12.01. | Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment o.. | |
| 12.01. | Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatme.. | |
| 10.01. | INSIDER SELL : Arrowhead Pharmaceuticals | |
| 07.01. | INSIDER SELL : Arrowhead Pharmaceuticals | |
English (USA)
English (UK)
English (Canada)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
